MonoSol Rx has licensed rights to its film drug delivery technology to MonoSol LLC, a separate company that develops water soluble technologies for a variety of industries.
The deal – financial terms of which were not provided – grants MonoSol LLC the right to use intellectual property that underpins the PharmFilm drug delivery technology in the fields of detergents, agrochemicals, oil and gas and water treatment.
MonoSol Rx CEO Keith Kendall said: “We have long been aware of the potential for our proprietary film technology to add substantive value to applications in a wide range of industries.”
He added that: “This is an important validation of the strength of our fundamental IP, and we are pleased to license our technology to MonoSol LLC for use outside of the pharmaceutical industry.”
MonoSol Rx and MonoSol LLC split in 2004. The latter firm was acquired by Kuraray in 2012.
At the time Kuraray said the move would allow it to become a “total global leader in the poval film business, not only for optical uses but also for industrial applications.”
MonoSol RX’s Pharmfilm technology, which is about the size of a postage stamp, is designed to rapidly dissolve on the tongue and release its active. It is regarded as suitable for patients who have difficulty swallowing more conventional medications.